A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.

Autor: Bobisse S; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.; Center for Cell Immunotherapy, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland., Bianchi V; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.; Center for Cell Immunotherapy, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.; Center for Experimental Therapeutics, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland., Tanyi JL; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA., Sarivalasis A; Center for Cell Immunotherapy, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland., Missiaglia E; Institute of Pathology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland., Pétremand R; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.; Center for Cell Immunotherapy, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland., Benedetti F; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.; Center for Cell Immunotherapy, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland., Torigian DA; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA., Genolet R; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.; Center for Cell Immunotherapy, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland., Barras D; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.; Center for Cell Immunotherapy, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland., Michel A; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.; Center for Cell Immunotherapy, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland., Mastroyannis SA; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA., Zsiros E; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.; Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Dangaj Laniti D; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.; Center for Cell Immunotherapy, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland., Tsourti Z; Laboratory of Biostatistics, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece., Stevenson BJ; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.; Center for Cell Immunotherapy, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland., Iseli C; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.; Bioinformatics Competence Center, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland., Levine BL; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA., Speiser DE; Center for Cell Immunotherapy, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland., Gfeller D; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.; Center for Cell Immunotherapy, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland., Bassani-Sternberg M; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.; Center for Cell Immunotherapy, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland., Powell DJ Jr; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA., June CH; Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA., Dafni U; Laboratory of Biostatistics, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece., Kandalaft LE; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.; Center for Cell Immunotherapy, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.; Center for Experimental Therapeutics, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland., Harari A; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.; Center for Cell Immunotherapy, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland., Coukos G; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland. george.coukos@chuv.ch.; Center for Cell Immunotherapy, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland. george.coukos@chuv.ch.

Publikováno v: Nature cancer [Nat Cancer] 2023 Oct; Vol. 4 (10), pp. 1410-1417. Date of Electronic Publication: 2023 Sep 21.

Delay in adjuvant chemotherapy administration for patients with FIGO stage I epithelial ovarian carcinoma is associated with worse survival; an analysis of the National Cancer Database.

Autor: Nasioudis D; Division of Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA. Electronic address: dimitrios.nasioudis@uphs.upenn.edu., Mastroyannis SA; Division of Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA., Ko EM; Division of Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA., Haggerty AF; Division of Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA., Cory L; Division of Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA., Giuntoli RL 2nd; Division of Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA., Kim SH; Division of Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA., Morgan MA; Division of Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA., Latif NA; Division of Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA.

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2022 Aug; Vol. 166 (2), pp. 263-268. Date of Electronic Publication: 2022 Jun 03.

Role of lymphadenectomy for apparent early stage uterine sarcoma; a comprehensive analysis of the National Cancer Database.

Autor: Nasioudis D; Division of Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA. Electronic address: dimitrios.nasioudis@uphs.upenn.edu., Mastroyannis SA; Division of Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA., Latif NA; Division of Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA., Ko EM; Division of Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA., Haggerty AF; Division of Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA., Kim SH; Division of Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA., Morgan MA; Division of Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA., Giuntoli RL 2nd; Division of Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA.

Publikováno v: Surgical oncology [Surg Oncol] 2021 Sep; Vol. 38, pp. 101589. Date of Electronic Publication: 2021 Apr 24.

Ovarian Sertoli-Leydig and granulosa cell tumor: comparison of epidemiology and survival outcomes.

Autor: Nasioudis D; Department of Obstetrics and Gynecology, Helen O'Dickens Women's Health Center, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, USA. dimitrios.nasioudis@uphs.upenn.edu., Mastroyannis SA; Department of Obstetrics and Gynecology, Helen O'Dickens Women's Health Center, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, USA., F Haggerty A; Department of Obstetrics and Gynecology, Helen O'Dickens Women's Health Center, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, USA., M Ko E; Department of Obstetrics and Gynecology, Helen O'Dickens Women's Health Center, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, USA., Latif NA; Department of Obstetrics and Gynecology, Helen O'Dickens Women's Health Center, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, USA.

Publikováno v: Archives of gynecology and obstetrics [Arch Gynecol Obstet] 2020 Aug; Vol. 302 (2), pp. 481-486. Date of Electronic Publication: 2020 Jun 09.

In Reply.

Autor: Albright BB; Department of Obstetrics and Gynecology, University of Pennsylvania Health System, Philadelphia, Pennsylvania., Shorter JM, Mastroyannis SA, Ko EM, Schreiber CA, Sonalkar S

Publikováno v: Obstetrics and gynecology [Obstet Gynecol] 2020 May; Vol. 135 (5), pp. 1226-1227.